A Russian vaccine developed at the Gamaleya Centre has been approved for use in the 37th state. This was reported by the Russian Direct Investment Fund.
On Thursday, the press service of the Russian Direct Investment Fund published a report on the receipt of registration of Sputnik V in Guatemala.
"The registration of the vaccine has been carried out under an accelerated procedure (emergency use authorization, EUA)," the statement said.
The Russian drug, developed at the Gamaleya Research Centre, has thus been approved for use in 37 countries as of today. Guatemala has become the third country to approve Sputnik V in Central America.
Earlier, we reported that the Ministry of Health updated the list of contraindications for vaccination against COVID-19.
Photo: Sputnik V official website